These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26513763)

  • 1. Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir.
    Fevery B; Susser S; Lenz O; Cloherty G; Perner D; Gilles L; De Locht P; Picchio G; De Meyer S; Sarrazin C
    J Clin Virol; 2015 Nov; 72():133-40. PubMed ID: 26513763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.
    Moreno C; Hezode C; Marcellin P; Bourgeois S; Francque S; Samuel D; Zoulim F; Grange JD; Shukla U; Lenz O; Ouwerkerk-Mahadevan S; Fevery B; Peeters M; Beumont M; Jessner W
    J Hepatol; 2015 May; 62(5):1047-55. PubMed ID: 25596313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays.
    Vermehren J; Bourlière M; Pol S; Marcellin P; Hyland RH; Jiang D; Brainard DM; Zeuzem S; Welzel TM
    J Clin Virol; 2017 Apr; 89():51-56. PubMed ID: 28259054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.
    Sarrazin C; Shiffman ML; Hadziyannis SJ; Lin A; Colucci G; Ishida H; Zeuzem S
    J Hepatol; 2010 Jun; 52(6):832-8. PubMed ID: 20385421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy.
    Fevery B; Susser S; Lenz O; Cloherty G; Perner D; Picchio G; Sarrazin C
    Antivir Ther; 2014; 19(6):559-67. PubMed ID: 24584086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.
    Vermehren J; Aghemo A; Falconer K; Susser S; Lunghi G; Zeuzem S; Colombo M; Weiland O; Sarrazin C
    J Hepatol; 2014 May; 60(5):913-9. PubMed ID: 24424305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.
    Sarrazin C; Dierynck I; Cloherty G; Ghys A; Janssen K; Luo D; Witek J; Buti M; Picchio G; De Meyer S
    J Clin Microbiol; 2015 Apr; 53(4):1264-9. PubMed ID: 25653396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study.
    Kessler HH; Cobb BR; Wedemeyer H; Maasoumy B; Michel-Treil V; Ceccherini-Nelli L; Bremer B; Hübner M; Helander A; Khiri H; Heilek G; Simon CO; Luk K; Aslam S; Halfon P
    J Clin Virol; 2015 Jun; 67():67-72. PubMed ID: 25959162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy.
    Ogawa E; Furusyo N; Murata M; Hayashi T; Shimizu M; Mukae H; Toyoda K; Hotta T; Uchiumi T; Hayashi J
    Antiviral Res; 2016 Feb; 126():35-42. PubMed ID: 26692214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.
    Kanda T; Nakamoto S; Sasaki R; Nakamura M; Yasui S; Haga Y; Ogasawara S; Tawada A; Arai M; Mikami S; Imazeki F; Yokosuka O
    Int J Med Sci; 2016; 13(4):310-5. PubMed ID: 27076789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
    Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S
    Antivir Ther; 2011; 16(2):173-80. PubMed ID: 21447866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
    Inoue T; Hmwe SS; Shimada N; Kato K; Ide T; Torimura T; Kumada T; Toyoda H; Tsubota A; Takaguchi K; Wakita T; Tanaka Y
    PLoS One; 2017; 12(1):e0170667. PubMed ID: 28118381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy.
    Ogawa E; Furusyo N; Murata M; Shimizu M; Toyoda K; Hotta T; Uchiumi T; Hayashi J
    Antivir Ther; 2017; 22(1):61-70. PubMed ID: 27632789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Eiraku K; Shimizu M; Harada Y; Mitsumoto F; Takayama K; Okada K; Kainuma M; Hayashi J
    Antiviral Res; 2013 Aug; 99(2):119-24. PubMed ID: 23684903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment.
    Wiesmann F; Naeth G; Berger A; Hirsch HH; Regenass S; Ross RS; Sarrazin C; Wedemeyer H; Knechten H; Braun P
    Med Microbiol Immunol; 2016 Jun; 205(3):263-8. PubMed ID: 26666643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients.
    Matsuura K; Tanaka Y; Hasegawa I; Ohno T; Tokuda H; Kurbanov F; Sugauchi F; Nojiri S; Joh T; Mizokami M
    J Clin Microbiol; 2009 Feb; 47(2):385-9. PubMed ID: 19091819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.